Triple

T11074426
Position Surface form Disambiguated ID Type / Status
Subject CD20 protein E261827 entity
Predicate targetOf P860 FINISHED
Object mosunetuzumab (bispecific antibody component)
Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
 E902883 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: mosunetuzumab (bispecific antibody component) | Statement: [CD20 protein, targetOf, mosunetuzumab (bispecific antibody component)]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: mosunetuzumab (bispecific antibody component)
Context triple: [CD20 protein, targetOf, mosunetuzumab (bispecific antibody component)]
  • A. isatuximab
    Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
  • B. daratumumab
    Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
  • C. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • D. Kymriah
    Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
  • E. nivolumab
    Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: mosunetuzumab (bispecific antibody component)
Triple: [CD20 protein, targetOf, mosunetuzumab (bispecific antibody component)]
Generated description
Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: mosunetuzumab (bispecific antibody component)
Target entity description: Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
  • A. isatuximab
    Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
  • B. daratumumab
    Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
  • C. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • D. Kymriah
    Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
  • E. nivolumab
    Nivolumab is a monoclonal antibody immunotherapy drug that blocks the PD-1 immune checkpoint to enhance the body’s anti-tumor response in various cancers.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d6aa9983c08190b0ef61603b69feac completed April 8, 2026, 7:20 p.m.
NER Named-entity recognition batch_69d7994e32fc8190a6591d9e82b68f75 completed April 9, 2026, 12:19 p.m.
NED1 Entity disambiguation (via context triple) batch_69e3c8cc77988190aad54f56dbd0f8cf completed April 18, 2026, 6:09 p.m.
NEDg Description generation batch_69e3cefc00148190a1850dc6e31523c3 completed April 18, 2026, 6:35 p.m.
NED2 Entity disambiguation (via description) batch_69e3d014a644819092c76aa02b573ca9 completed April 18, 2026, 6:40 p.m.
Created at: April 8, 2026, 9:26 p.m.